Consumer medicine information

Metformin generichealth 1000

Metformin hydrochloride

BRAND INFORMATION

Brand name

Metformin Generichealth 1000

Active ingredient

Metformin hydrochloride

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Metformin generichealth 1000.

What is in this leaflet?

Please read this leaflet carefully before you start to take these tablets. Keep it until all the prescribed course of Metformin generichealth 1000 has been finished, as you may want to read it again. This leaflet may not contain all the information about this medicine that you would like to know. It does not take the place of talking to your doctor, pharmacist or diabetes educator.

If you have any concerns about taking this medicine, please talk to your doctor or pharmacist or diabetes educator. All medicines have risks and benefits. Your doctor has weighed the risks of you taking Metformin generichealth 1000 against the benefits expected for you.

What is in your medicine?

  • Metformin generichealth 1000: Each film coated tablet contains 1000 mg of the active ingredient metformin hydrochloride.
  • Other inactive ingredients. Sodium starch glycollate, maize starch, povidone, colloidal anhydrous silica, magnesium stearate, hypromellose, titanium dioxide (E171), propylene glycol, macrogol 6000 and purified talc.

What is your medicine for?

Metformin generichealth 1000 is one of the groups of medicines called oral hypoglycaemics, which work by reducing the level of sugar in the blood in people with diabetes mellitus.

Diabetes mellitus is a condition in which the blood glucose levels are not adequately controlled.

There are two types of diabetes:

  • Type 1 which is called insulin dependent diabetes or juvenile onset diabetes, when insulin alone is not enough to control blood glucose levels.
  • Type 2 which is called Non insulin Dependent Diabetes Mellitus (NIDDM) or maturity onset diabetes.

People with type 2 diabetes are not able to make enough insulin or respond normally to the insulin their bodies make. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems including kidney damage, amputation and blindness.

Diabetes is also closely linked to heart disease. The main goal of treating diabetes is to lower your blood sugar to a normal level. High blood sugar can he lowered by diet and exercise, by a number of medicines taken by mouth, and by insulin injections.

Metformin generichealth 1000 tablets are used for the treatment of type 2 diabetes which usually only occurs in adults and does not need insulin but does not respond to diet and exercise.

Metformin generichealth 1000 is especially useful in people who are overweight and in whom diet and exercise alone are not enough to lower high blood glucose levels (hyperglycaemia).

Metformin generichealth 1000 can be used alone, or in combination with other medicines for treating diabetes. Metformin generichealth 1000 can also be used in patients with type 1 diabetes mellitus where insulin alone is not enough to control blood glucose levels.

Metformin generichealth 1000 is not recommended for use in children, except for those with insulin- resistant diabetes who are being treated in hospital.

Before you take your medicine

Make sure that it is safe for you to take Metformin generichealth 1000. Do not take Metformin generichealth 1000 if you answer YES to any of the following questions. If you are not sure, then ask your doctor or pharmacist.

  • Are you allergic to any of the ingredients in this medicine?
  • Do you have type 1 diabetes mellitus that is well controlled by insulin alone?
  • Do you have type 2 diabetes that is already well controlled by diet alone?
  • Are you suffering from diabetic ketoacidosis (a symptom of uncontrolled diabetes, in which substances called ketone bodies build up in the blood - you may notice this as an unusual fruity odour on your breath, difficulty breathing, confusion and frequent urination)?
  • Are you allergic to any other medicines, foods, dyes or preservatives?
  • Do you drink alcohol excessively or suffer from alcohol dependence? Alcohol can affect the control of your diabetes. Drinking excessive amounts of alcohol while you are being treated with Metformin generichealth 1000 may also lead to serious side effects. Your doctor may suggest you stop drinking or reduce the amount of alcohol you drink.
  • Do you have any problem with your liver or kidneys?
  • Do you have a heart disorder such as heart failure or have you suffered a heart attack recently?
  • Are you, or could you be, pregnant? lnsulin is more suitable for controlling blood glucose during pregnancy. Your doctor win replace Metformin generichealth 1000 with insulin while you are pregnant.
  • Are you breast-feeding? Metformin generichealth 1000 is not recommended while you are breastfeeding. Your doctor will discuss with you the other options of treatment.
  • Are you likely to have surgery or a scan involving the use of X-rays, including dental surgery within the next few days? Some types of X-ray procedures require an injection of iodinated contrast (dye). Using this type of dye while you are taking Metformin generichealth 1000 may cause severe kidney problems and increase the risk of a serious condition called lactic acidosis. Your doctor will tell you when to temporarily stop taking the tablets before the X-ray and when it is safe to restart them.
  • Do you have any problems with your circulation causing, for example, frequent cramp in your calves or leg ulcers that do not heal?
  • Do you have a fever or are you ill in any other way?
  • Are you on a special diet?
  • Are you suffering from an excessive loss of body water?
  • Do you have breathing problems?
  • Do you suffer from the symptoms of blood clots in the lungs? (Symptoms include coughing, shortness of breath, chest pain and a fast heart rate.)
  • Are you suffering from severe blood loss or shock?
  • Are you suffering from gangrene?
  • Are you suffering from inflammation of the pancreas? (Symptoms include severe stomach pain often with nausea and vomiting.)

Patients who are already on insulin should only be started on a course of treatment with Metformin generichealth 1000 in hospital.

Metformin generichealth 1000 should not be taken by children, except for those with insulin-resistant diabetes who are being treated in hospital.

Other Medicines

Other medicines, including some you could buy without a prescription, may interact with these tablets. If you are taking or intend to take any other medicine during treatment with Metformin generichealth 1000, check with your doctor or pharmacist that it is safe to do so.

This is particularly important in the case of:

  • other antidiabetic drugs (eg. insulin, guar gum), sulphonylureas such as gliclazide (eg. Diarnicron Glyade), glipizide (eg. Minidiab, Melizide), glimepiride (eg. Amaryl, Dimirel), repaglinide (Novonorm);
  • anti inflammatory pain killers such as salicylates or pyrazolones;
  • medicines used to treat high blood pressure and some heart conditions (beta blockers, calcium channel blockers and ACE inhibitors, eg. metoprolol (Betaloc, Minax), nifedipine (Adalat, Adefin), enalapril (Renitec), Lisinopril (Zestril);
  • cimetidine (Tagamet Magicul) a medicine used to treat reflux and ulcers;
  • corticosteroids such as prednisone (Panafcort, Sone) and Cortisone (Cortate);
  • tablets that thin the blood (anticoagulants such as warfarin. Coumarin, Marevan);
  • fluid tablets (thiazide diuretics such as Moduretic, Aprinox, Arnizide);
  • thyroid preparations such as thyroxine (Oroxine);
  • contrast media given as injections when you undergo examination using X-rays; for example Ultravist. One ingredient called "propylene glycol" may cause allergic reactions.

Your doctor or pharmacist can tell you what to do if you are taking any of these medicines. They also have more information on medicines to be careful with or to avoid while taking Metformin generichealth 1000.

Do not take Metformin generichealth 1000 after the expiry date printed on the pack has passed.

Do not take Metformin generichealth 1000 if the foil seal is broken or the pack shows signs of tampering.

How does Metformin generichealth 1000 work?

Metformin generichealth 1000 belongs to a group of medicines called biguanides. Metformin generichealth 1000 lowers high levels of blood glucose by helping your body to make better use of the insulin produced by your pancreas.

If your blood glucose is not properly controlled, you may experience hypoglycaemia (low blood glucose) or hyperglycaemia (high blood glucose).

HYPOGLYCAEMIA
Hypoglycaemia (low blood glucose) can occur suddenly. Initial signs include:

  • Weakness, trembling or shaking;
  • Sweating;
  • Light-headedness, dizziness, headache or lack of concentration;
  • Irritability, tearfulness or crying;
  • Hunger;
  • Numbness around the lips and tongue.

If not treated promptly, these may progress to:

  • Loss of co-ordination;
  • Slurred speech;
  • Confusion;
  • Fits or loss of consciousness.

HYPERGLYCAEMIA
Hyperglycaemia (high blood glucose) usually occurs more slowly than hypoglycaemia. Signs of hyperglycaemia may include:

  • Lethargy or tiredness;
  • Headache;
  • Thirst;
  • Passing large amounts of urine;
  • Blurred vision;

Long term hyperglycaemia can lead to serious problems with your heart, eyes, kidneys or blood circulation.

Taking your medicine

Your doctor or pharmacist will have told you about this, and you should always follow their instructions carefully. The dose varies from patient to patient. The usual starting dose is one 500 mg tablet once or twice a day with breakfast and the evening meal. Your doctor may increase or decrease the dose depending on your blood glucose levels. The maximum recommended dose is 1000 mg three times a day.

Elderly patients may need smaller doses.

If your child has diabetes which is resistant to insulin and is being treated in hospital, your child's doctor will decide the dose.

The tablets should be taken with a glass of water during or after meals. This will lessen the chance of a stomach upset. Do not chew the tablets but swallow them whole. The 500mg tablet may be divided in half along the breakline, if advised by your doctor.

Metformin generichealth 1000 will help control diabetes but will not cure it. Most people need to take Metformin generichealth 1000 for long periods of time.

What to do if you forget to take Metformin generichealth 1000

If you miss a dose, take it as soon as you remember (with food) unless it is nearly time for the next dose. If it nearly time for the next dose skip the missed dose. Never double-up on the next dose to make up for the one missed.

What should you do if you take too many Metformin generichealth 1000

If you swallow too many tablets or someone else accidentally takes your medicine, contact your doctor, pharmacist or nearest hospital straight away or call the Poisons Information Centre (telephone 131126). Do this even If there are no signs of discomfort or poisoning.

If you take too much Metformin generichealth 1000, you may feel sleepy, very tired, and sick, vomit, have trouble breathing and have unusual muscle pain, stomach pain or diarrhoea. These may be early signs of a serious condition called lactic acidosis (build up of lactic acid in the blood).

You may also experience symptoms of hypoglycaemia (low blood glucose). This usually only happens if you take too much Metformin generichealth 1000 together with other medicines for diabetes or with alcohol.

While taking your medicine

Make sure that you, your friends, family and work colleagues can recognise the symptoms of hypo glycaemia and hyperglycaemia and know how to treat them.

If you plan to have surgery (including dental surgery) or anaesthesia inform your doctor, dentist or anaesthetist that you are taking Metformin generichealth 1000 tablets.

If you do experience any signs of hypoglycaemia (low blood glucose), raise your blood glucose quickly by taking one of the following:

  • 5-7 jelly beans
  • 3 teaspoons of sugar or honey
  • Half a can of non-diet soft drink
  • 2-3 concentrated glucose tablets.

Unless you are within 10-15 minutes of your next meal or snack, follow up with extra carbohydrates such as plain biscuits, fruit or milk.

Taking this extra carbohydrate will prevent a second drop in your blood glucose level. Metformin generichealth 1000 dose not normally cause hypoglycaemia although you may experience it while taking other medicines for diabetes such as insulin or sulphonylureas.

If you experience any of the signs of hyperglycaemia (high blood glucose), contact your doctor immediately. The risk of hyperglycaemia is increased in the following situations:

  • Uncontrolled diabetes;
  • Illness, infection or stress;
  • Taking less Metformin generichealth 1000 than prescribed;
  • Taking certain other medicines;
  • Too little exercise;
  • Eating more carbohydrates than usual.

Tell your doctor if any of the following happen:

  • You become ill;
  • You become dehydrated;
  • You are injured;
  • You have a fever;
  • You have a serious infection;
  • You are having surgery (including dental surgery);
  • You are having X-ray procedures that require injection of contrast agents.

Your blood glucose may become difficult to control at these times. You may also be more at risk of developing a serious condition called lactic acidosis. At these times your doctor may replace Metformin generichealth 1000 with insulin.

Before starting any new medicines, tell your doctor or pharmacist that you are taking Metformin generichealth 1000.

If you become pregnant while taking Metformin generichealth 1000 tell your doctor immediately. Visit your doctor regularly for check ups.

Your doctor may want to check your kidneys, liver, heart, blood and vitamin B12 levels while you are taking Metformin generichealth 1000.

Make sure you check your blood glucose levels regularly.

This is the best way to tell if your diabetes is being controlled properly. Your doctor or diabetes educator will show you how and when to do this.

When you start treatment with Metformin generichealth 1000, it can take up to three weeks for your blood glucose levels to be properly controlled. Prolonged treatment with Metformin generichealth 1000 can deplete reserves of Vitamin B12 and this may cause anaemia. Regular blood tests for kidney function and Vitamin B12 should therefore be carried out.

Carefully follow the advice of your doctor and dietician on diet, drinking alcohol and exercise.

Things you must not do:

  • Do not skip meals while taking Metformin generichealth 1000.
  • Do not stop taking Metformin generichealth 1000 or change the dose without checking with your doctor.
  • Do not give Metformin generichealth 1000 to anyone else even if they have the same condition as you.
  • Do not use Metformin generichealth 1000 to treat any other condition unless your doctor tells you to.

Things to be careful of:

Metformin generichealth 1000 tablets on their own should not affect your ability to drive, but if you are also taking other medicines which lower the blood sugar it is possible that their combined effects could make you feel faint, dizzy, weak or jittery.

If this happens you should not drive or operate any machinery until you have recovered. If you are driving, be especially careful not to let your blood glucose levels fall too low.

Low blood glucose levels may slow your reaction time and affect your ability to drive or operate machinery. Drinking alcohol can make this worse.

If you become sick with cold, fever or flu, it is very important to continue eating your normal meals.

Your diabetes educator can give you a list of foods to eat on sick days. When you are travelling, it is a good idea to:

  • Wear some form of identification (eg. bracelet) showing you have diabetes.
  • Carry some form of sugar to treat hypoglycaemia if it occurs, for example. sugar sachets or jelly beans.
  • Carry emergency food rations in case of a delay, for example, dried fruit, biscuits or muesli bars.
  • Bring enough Metformin generichealth 1000 with you, so you don't miss any doses.

Side effects

Any medicine can have side effects. Metformin generichealth 1000 is usually well tolerated, but sometimes can cause stomach upsets such as feeling sick (nausea), vomiting, diarrhoea, loss of appetite or a metallic taste.

If such side effects do occur, they often get better after the first few weeks. Taking Metformin generichealth 1000 with meals can help reduce nausea and diarrhoea. Rarely, skin reactions may occur. If you notice a red skin rash ask your doctor for advice about continuing with the tablets.

Report any side effects to your doctor promptly. If you are over 65 years of age, you may have an increased chance of getting side effects.

Tell your doctor immediately or go to Accident and Emergency at the nearest hospital if you notice any of the following:

  • stomach or abdominal pain, nausea, vomiting;
  • muscle pains, feeling weak, tired or generally unwell, have breathing problems, confusion or drowsiness, dizziness or light-headedness, shivering, feeling extremely cold, slow heart beat. In this case you must contact your doctor immediately or go to the nearest hospital accident and emergency department since these symptoms may indicate the uncommon but serious condition of lactic acidosis. Lactic acidosis is a very rare but serious side effect requiring urgent medical treatment in hospital. The risk of lactic acidosis is higher in some people, including the elderly, those taking doses greater than 2000 mg a day, those drinking excessive amounts of alcohol and people with kidney problems.

If you think you have any other side effects from taking this medicine, please tell your doctor or pharmacist.

Storing your medicine

  • Do not take the tablets after the expiry date on the label.
  • Do not keep the tablets above 25°C.
  • Store the tablets in their original blister pack in a cool dry place.
  • Keep all medicines out of reach of children - preferably in a locked cupboard or medicine cabinet.
  • Do not store Metformin generichealth 1000 or any other medicine in the bathroom or near a sink. Heat and dampness can destroy some medicines.
  • Do not leave Metformin generichealth 1000 in the car or on window sills.

If your doctor tells you to stop taking Metformin generichealth 1000, or your tablets have reached their expiry date, ask your pharmacist what to do with any that are left over.

Presentation

10000 mg Tablet AUST R 164469

White, capsule-shaped film-coated tablets, with a breakline on one side, in blister packs of 10, 30, 60 and 90 tablets. The tablets are gluten free.

Sponsor

Generic Health Pty Ltd
Level 1, 1102 Toorak Rd
CAMBERWELL VIC 3124

This leaflet was prepared in November 2015

Published by MIMS October 2017

BRAND INFORMATION

Brand name

Metformin Generichealth 1000

Active ingredient

Metformin hydrochloride

Schedule

S4

 

Name of the medicine

Metformin hydrochloride.

Excipients.

Sodium starch glycollate, maize starch, povidone, colloidal anhydrous silica, magnesium stearate, hypromellose, titanium dioxide, propylene glycol, Macrogol 6000 and purified talc.

Description

Chemical name: 1, l-dimethylbiguanide hydrochloride. Molecular formula: C4H11N5.HCl. MW: 165.6. CAS number. 1115-70-4.
Metformin hydrochloride is a white crystalline powder which is odourless or almost odourless and hygroscopic. It is freely soluble in water, slightly soluble in ethanol (96%), and practically insoluble in chloroform and in ether.
Active: Metformin hydrochloride. Inactive: Sodium starch glycollate, maize starch, povidone, colloidal anhydrous silica, magnesium stearate, hypromellose, titanium dioxide, propylene glycol, Macrogol 6000 and purified talc.

Pharmacology

Metformin is an antihyperglycaemic agent which improves glucose tolerance in NIDDM subjects lowering both basal and post-prandial plasma glucose. Metformin causes an increased peripheral uptake of glucose by increasing the biological efficiency of available exogenous or endogenous insulin. The mode of action of metformin may be linked to increased insulin sensitivity; it does not stimulate insulin release but does require the presence of insulin to exert its antihyperglycaemic effect. Possible mechanisms of action include inhibition of gluconeogenesis in the liver, delay in glucose absorption from the gastrointestinal tract and an increase in peripheral uptake of glucose. Metformin has an antiketogenic activity which is comparable, though somewhat inferior to insulin itself. Metformin has a modest favourable effect on serum lipids, which are often abnormal in NIDDM patients.

Pharmacokinetics.

Absorption.

A randomised, open, balanced, crossover bioequivalence study using Formin tablets 500 mg film-coated tablets in 26 healthy subjects showed that peak plasma concentrations occurred at between 2 to 3 hours after a single dose of 500 mg. The mean peak plasma concentration was 0.721 mg/mL for the test product. Metformin was detected in plasma for 36 hours post dose in all subjects. The Tmax values were comparable for both reference and test formulations. The 90% confidence limit for AUC0-t and AUC0-∞ (as a measure of the extent of absorption) of the test product Formin tablets (Meditab metformin 500 mg) compared to the reference product (metformin 500 mg Diabex Alphapharm) was within acceptable limits. No adverse events were reported. In a bioequivalence study comparing Metformin generichealth 1000 1 g tablets with the reference product (Diabex 1 g tablets), the mean Cmax was 1.4 microgram/mL of the test product and 1.5 microgram/mL for the reference. The mean Tmax, AUC0-t and AUC0-∞ were comparable for both products and the 90% confidence intervals were within the limits required to demonstrate bioequivalence.
After oral administration, metformin hydrochloride is absorbed along the entire gastrointestinal mucosa. Studies using single oral doses of metformin tablets indicate that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than increase in elimination. At usual clinical doses and dosing schedules of metformin tablets, steady state plasma concentrations are reached in 24 to 48 hours and are generally less than 1 microgram/mL. Food decreases the extent and slightly delays the absorption of metformin. However the clinical relevance of this is unknown. During controlled clinical trials, maximum metformin plasma levels did not generally exceed 5 micrograms/mL even at maximum doses.

Distribution.

Metformin is negligibly bound to plasma proteins.

Metabolism.

Metformin is excreted unchanged in the urine and does not undergo hepatic metabolism.

Excretion.

In patients with decreased renal function (based on measured creatinine clearance) the plasma half life of metformin is prolonged and renal clearance is decreased in proportion to the decrease in creatinine clearance, e.g. if creatinine clearance is 10-30 mL/min, renal clearance is reduced to 20% of normal. No pharmacokinetic data are available for hepatic insufficiency.

Clinical Trials

The prospective randomised (UKPDS) study has established the long-term benefit of intensive blood glucose control in type 2 diabetes. Analysis of the results for overweight patients treated with metformin after failure of diet alone showed:
A significant reduction of the absolute risk of any diabetes-related complication in the metformin group (29.8 events/1000 patient-years) versus diet alone (43.3 events/1000 patient years), p = 0.0023, and versus the combined sulfonylurea and insulin monotherapy groups (40.1 events/1000 patient-years), p=0.0034.
A significant reduction of the absolute risk of diabetes-related mortality: metformin 7.5 events/1000 patient-years, diet alone 12.7 events/1000 patient-years, p = 0.017.
A significant reduction of the absolute risk of overall mortality: metformin 13.5 events/1000 patient-years versus diet alone 20.6 events/1000 patient-years (p = 0.011), and versus the combined sulfonylurea and insulin monotherapy groups 18.9 events/1000 patient-years (p = 0.021).
A significant reduction in the absolute risk of myocardial infarction: metformin 11 events/1000 patient-years, diet alone 18 events/1000 patient-years (p = 0.01).

Indications

Metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone, does not result in adequate glycaemic control. It may be used as initial treatment, or in sulphonylurea failures, either alone or in combination with a sulphonylurea and other oral agents or as adjuvant therapy in insulin dependent diabetes.

Contraindications

Juvenile diabetes mellitus that is uncomplicated and well regulated on insulin.
Diabetes mellitus regulated by diet alone.
During or immediately following surgery where insulin is essential.
Hypersensitivity to metformin hydrochloride or to any of the excipients.
Diabetic ketoacidosis, diabetic pre-coma.
Renal failure or renal dysfunction (creatinine clearance < 60 mL/min).
Acute conditions with the potential to alter renal function such as: dehydration; severe infection; shock; intravascular administration of iodinated contrast agents.
Acute or chronic disease which may cause tissue hypoxia such as: cardiac failure; recent myocardial infarction; respiratory failure; pulmonary embolism; shock; acute significant blood loss; sepsis; gangrene; pancreatitis.
Severe hepatic insufficiency.
Acute alcohol intoxication.
Alcoholism.
Lactation.

Precautions

Lactic acidosis is a rare but serious metabolic complication which can occur due to metformin accumulation during treatment with metformin. When it occurs, it is fatal in approximately 50% of cases. Lactic acidosis is a medical emergency and must be treated in hospital immediately. The risk of lactic acidosis increases with the degree of renal dysfunction and the patient’s age. Reported cases have occurred primarily in diabetic patients with significant renal insufficiency, often in the setting of multiple concomitant medical/surgical problems and multiple concomitant medications, Special caution should be taken in the elderly due to the decrease of renal function with age.
The reported incidence of lactic acidosis in patients receiving metformin is very low (approximately 0.03 cases per 1000 patient years, with approximately 0.015 fatal cases per 100 patient years). The onset is often subtle and accompanied by non specific symptoms such as malaise, myalgia, respiratory distress, increasing somnolence and non specific abdominal distress. Lactic acidosis may also occur in association with a number of pathophysiological conditions, including diabetes mellitus, and when there is significant tissue hypoperfusion and hypoxaemia. Lactic acidosis is characterised by acidosis (decreased blood pH), elevated lactate levels with increased lactate/pyruvate ratio and electrolyte disturbances with increased anion gap.

Heart failure.

Type 2 diabetic patients with heart failure are at an increased risk of hypoperfusion and possible renal insufficiency. Renal insufficiency is a risk factor for systemic accumulation of metformin and consequently lactic acidosis. Careful monitoring of renal function is recommended when metformin is used in patients with cardiac failure. The major risk of cardiac insufficiency is hypoxia. When metformin is implicated as the cause of lactic acidosis, metformin plasma levels greater than 5 microgram/mL are generally found. Underlying renal disease, or deterioration in renal function, results in reduced clearance of metformin and drug accumulation and are therefore major risk factors in lactic acidosis. The risk of lactic acidosis may therefore be significantly decreased by regular monitoring of renal function in patients taking metformin and those patients taking concomitant diuretics and by the use of the minimum effective dose of metformin. In addition, metformin therapy should be temporarily stopped in the presence of any condition associated with hypoxaemia or dehydration, in patients suffering from serious infections or trauma (particularly if gastrointestinal disturbances are noted or acidosis is suspected) and in those undergoing surgery.

Impaired hepatic function.

Since impaired hepatic function has been associated with some cases of lactic acidosis, metformin should be avoided in patients with clinical or laboratory evidence of hepatic disease.
Radiological studies involving the use of intravascular iodinated contrast materials (for example intravenous urogram, intravenous cholangiography, angiography, any computed tomography scans with intravascular contrast materials) can lead to acute alteration of renal function and have been associated with lactic acidosis in patients receiving metformin. Therefore in patients with normal renal function, metformin should be stopped at the time of the study and not recommenced for 48 hours and only after renal function has been reevaluated and found to be normal.
Alcohol is known to potentiate the effects of metformin on lactate metabolism. Patients should therefore be warned against excessive alcohol intake, acute or chronic, while taking metformin.
Periodic assessment of renal, hepatic and cardiovascular function is recommended during prolonged periods of treatment with metformin. Patients receiving continuous metformin therapy should have an annual estimation of Vitamin B12 levels because of reports of decreased vitamin B12 absorption.

Use in the elderly.

The risk of lactic acidosis, in association with metformin, is increased in elderly patients on long-term therapy due to the physiological alteration of the renal function and the possible accumulation of metformin. Metformin may be used in the elderly if contraindications and precautions are respected, the dosage is frequently reviewed and renal function monitored. Decreased renal function in elderly patients is frequent and asymptomatic. Caution should be exercised in situations where renal function may become impaired.

Carcinogenesis, mutagenesis, impairment of fertility.

Long term carcinogenicity studies have been performed in rats (dosing duration 104 weeks) and mice (dosing duration 91 weeks) at doses up to and including 900 and 1500 mg/kg/day respectively. These doses are approximately two to three times the recommended human daily dose on a body surface area basis. No evidence of carcinogenicity with metformin was found in either male or female mice. Similarly there was no tumorigenic potential observed with metformin in male rats. However an increased incidence of benign stromal uterine polyps was seen in female rats treated with 900 mg/kg/day. No evidence of a mutagenic potential of metformin was found in the Ames test (S. typhirmurium), gene mutation test (mouse lymphoma cells), chromosomal aberrations test (human lymphocytes), or in vivo micronuclei formation test (mouse bone marrow). Fertility of male or female rats was unaffected by metformin administration at doses of up to 600 mg/kg/day, or approximately twice the maximum recommended daily dose on a body surface area basis.

Use in pregnancy.

(Category C)
It is important to achieve strict normoglycaemia during pregnancy. Oral hypoglycaemic agents should be replaced by insulin.
Metformin was not teratogenic in rats and rabbits at doses up to 600 mg/kg/day, or about two times the maximum recommended human daily dose on a body surface area basis. Determination of fetal concentrations demonstrated a partial placental barrier to metformin. Because animal reproduction studies are not always predictive of human response, any decision to use this drug should be balanced against the benefits and risks.
Recent information suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities. Oral hypoglycaemics may enter the fetal circulation and cause neonatal hypoglycaemia. There is a consensus among experts that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible.

Use in lactation.

Studies in lactating rats show that metformin is excreted into milk and reaches levels comparable to those in plasma. Similar studies have not been conducted in nursing mothers, but caution should be exercised in such patients, and a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Use in children.

Metformin is not recommended for use in children except those with insulin resistant diabetes who are being treated in hospital.

Warnings.

Hypoglycaemia.

Hypoglycaemia does not occur in patients receiving metformin hydrochloride alone under usual circumstances of use, but could occur when calorie intake is deficient, when strenuous exercise is not compensated by calorie supplementation, or during concomitant use with other glucose-lowering agents (such as sulphonylureas) or ethanol.
Elderly, debilitated or malnourished patients and those with adrenal pituitary insufficiency or alcohol intoxication are particularly susceptible to hypoglycaemic effects.
The effectiveness of oral antidiabetic drugs in lowering blood glucose to a targeted level decreases in many patients over a period of time. This phenomenon, which may be due to progression of the underlying disease or to a diminished responsiveness to the drug, is known as secondary failure, to distinguish it from primary failure in which the drug is ineffective during initial therapy. Should secondary failure occur with metformin HCl or sulphonylurea monotherapy, combined therapy with metformin HCl and sulphonylurea may result in a response. Should secondary failure occur with combined metformin HCl/sulphonylurea therapy, it may be necessary to initiate insulin therapy. Metformin HCl alone does not usually cause hypoglycaemia, although it may occur when metformin HCl is used in conjunction with oral sulphonylureas. When initiating combination therapy, the risks of hypoglycaemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients.

Interactions

Cimetidine.

Reduced clearance of metformin has been reported during cimetidine therapy, so a dose reduction should be considered. Other cationic drugs such as amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim and vancomycin are eliminated by renal tubular secretion and theoretically have the potential to compete for common renal tubular transport systems with metformin. Careful patient monitoring is recommended in situations where cationic medications which are excreted via the proximal renal tubular secretory system are coadministered with metformin.

Anticoagulants.

Metformin increased the elimination rate of vitamin K antagonists. Consequently, the prothrombin time should be closely monitored in patients in whom metformin and vitamin K antagonists are being coadministered. Cessation of metformin in patients receiving vitamin K antagonists can cause marked increases in the prothrombin time.

Nifedipine.

A single dose metformin/nifedipine drug interaction study in normal healthy volunteers demonstrated that coadministration of metformin and nifedipine increased plasma metformin Cmax and AUC by 20 and 9% respectively, and increased the amount of metformin excreted in the urine. Tmax and half life of metformin were unaffected. Nifedipine appears to enhance the absorption of metformin. Metformin had minimal effects on the pharmacokinetics of nifedipine.

Sulphonylureas and repaglinide.

During concomitant therapy with sulphonylureas or repaglinide, blood glucose should be monitored because combined therapy may cause hypoglycaemia.

Beta-blockers.

Coadministration of metformin and β-blockers may result in a potentiation of the anti hyperglycaemic action. In addition, some of the premonitory signs of hypoglycaemia, in particular tachycardia may be masked. Monitoring of blood glucose should be undertaken during dosage adjustment of either agent.

ACE inhibitors.

Coadministration of metformin and ACE inhibitors may result in a potentiation of the antihyperglycaemic action. Monitoring of blood glucose should be undertaken during dosage adjustment of either agent.

Calcium channel blockers.

Calcium channel blockers may affect glucose control in diabetic patients; regular monitoring of glycaemic control is recommended.

Alcohol.

Alcohol may make the signs of hypoglycaemia less clear and delayed hypoglycaemia may occur. The CNS depressant effects of alcohol plus hypoglycaemia can make driving or the operation of dangerous machinery much more hazardous. There is increased risk of lactic acidosis in acute alcohol intoxication, particularly with fasting, malnutrition or hepatic insufficiency.

Thiazide diuretics.

Thiazide therapy may impair glucose tolerance. Dosage adjustment of metformin may be required.

Thyroid products.

Thyroid products tend to produce hyperglycaemia and may lead to loss of control.

Corticosteroids.

Corticosteroids tend to produce hyperglycaemia and may lead to loss of control.

Iodinated contrast media.

Metformin should be temporarily withheld in patients undergoing radiological studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function (see Precautions).

Other.

Phenothiazines, oestrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics and isoniazid tend to produce hyperglycaemia and patients receiving concomitant administration of any of these drugs with metformin should be closely observed to maintain glycaemic control.

Laboratory tests.

No information is available.

Adverse Effects

Gastrointestinal.

Very common: Mild gastrointestinal symptoms (such as diarrhoea, nausea, vomiting) are most frequent reactions to metformin (> 1/10), especially during the initial treatment period. These symptoms are generally transient and resolve spontaneously during continued treatment. Gastrointestinal symptoms can possibly be avoided if metformin is taken with meals and the dose is increased slowly. Occasionally a temporary dose reduction can be considered. Occurrence of gastrointestinal symptoms, once a patient is stabilised on any dose of metformin could be due to lactic acidosis or other serious disease.

Systemic/metabolic.

Very rare: Lactic acidosis (see Precautions) is a very rare (< 1/10,000) but serious metabolic complication that can occur due to metformin accumulation during treatment with metformin.
The onset of lactic acidosis is often subtle and accompanied by non specific symptoms such as malaise, myalgia, respiratory distress, increasing somnolence and non specific abdominal distress. There may be associated hypothermia, hypotension and resistant bradyarrhythmias with more marked acidosis.
The patient and the patient's doctor must be aware of the possible importance of such symptoms and the patient should be instructed to notify the doctor immediately if they occur. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonaemia). Lactic acidosis is a medical emergency that must be treated in hospital. In a patient with lactic acidosis who is taking metformin, the drug should be discontinued immediately and general supportive measures should be instituted promptly.

Dermatological.

Mild erythema has been reported in some hypersensitive individuals, but the incidence is very rare. (< 1/10,000).

Haematological.

A decrease of Vitamin B12 absorption with a decrease in serum levels has been observed in patients treated long term with metformin, and appears to be generally without clinical significance’ (<1/10,000). Therefore, serum B12 levels should be appropriately monitored (annually) or periodic parenteral B12 supplementation considered. Initial and periodic monitoring of haematological parameters (e.g. haemoglobin/ haematocrit and red blood cell indices) should be performed at least on an annual basis.

Other.

Common: metallic taste (3%).

Dosage and Administration

Life threatening lactic acidosis can occur due to accumulation of metformin. Risk factors include renal impairment, old age and high doses of metformin above 2 g/day. It is important that the tablets are taken in divided doses with meals. Initially 500 mg should be taken once or twice a day with breakfast and evening meal. If necessary the dose may be increased over a few weeks up to 1 g three times per day. The dose should be titrated with gradual dose increments until the desired effect is obtained, 500 mg three times a day is often sufficient to obtain diabetic control. If necessary, the dose can be increased to 1 g three times daily, which is the maximum recommended daily dose. Control may be obtained within a few days but occasionally requires up to two weeks. Once control has been obtained, the dosage should be reviewed and reduced to the lowest maintenance level consistent with good diabetic control. If dose titration has been achieved with one tablet strength, then the patient's response should be reassessed if a different strength or dose schedule is commenced. Metformin should be frequently reviewed in patients stabilised on metformin, especially if they develop an illness, as they may tolerate the drug less well, particularly if the illness is accompanied by a decrease in renal function. If necessary, metformin should be ceased for a few days during an illness and then restarted at low dosage, as for initial therapy.
The action of metformin is progressive and no final assessment of the patient’s real response should be made before the 21st day of treatment; blood sugar estimations are recommended during the initial 15 days of stabilisation.
Metformin will not produce a hypoglycaemic state when used alone; however, due to its action in increasing insulin effectiveness, care must be taken when metformin is initially administered with parenteral doses of insulin.

Elderly.

The initial maintenance dosing of metformin should be conservative in elderly patients, due to the potential for decreased renal function in this population. Any dosage adjustment should be based on a careful assessment of renal function. Generally, elderly patients should not be titrated to the maximum dose of metformin.

Debilitated patients.

In debilitated or malnourished patients, the dosing should be conservative and based on careful assessment of renal function.

Overdosage

Hypoglycaemia has not been seen with ingestion of up to 85 g of metformin alone, although lactic acidosis has occurred in such circumstances, The onset of lactic acidosis is often subtle and accompanied only by non specific symptom such as malaise, myalgia, respiratory distress, increasing somnolence and non specific abdominal distress. There may be associated hypothermia, hypotension and resistant bradyarrhythmias with more marked acidosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis, such as ketonuria and ketonaemia.

Treatment.

Lactic acidosis should be feared in diabetic metformin treated patients with overdose. Lactic acidosis is diagnosed and monitored by measuring serum electrolytes, arterial pH and pCO2 and arterial lactate plasma level.
The aim of treatment is to manage any underlying disorder and in some cases this will be sufficient to enable the body’s homeostatic mechanism to correct the acid base imbalance. The advantages of more active treatment of the acidosis must be balanced against the risks, including over-alkalinisation with sodium bicarbonate. Because metformin hydrochloride is dialysable (with a clearance of up to 170 mL/min under good haemodynamic conditions), prompt haemodialysis is recommended to correct the acidosis and remove the accumulated metformin.

Presentation

Tablets.

1000 mg: white, film-coated, capsule-shaped, biconvex tablet plain on one side and a breakline on the other. Available in pack size of 10, 30, 60 and 90’s PVC/PE/PVDC/Al blister pack.

Storage

Store below 25°C.

Poison Schedule

S4.